Weight-Loss Injections Linked to Increased Risk of Nail Problems, Study Finds
Research indicates that users of popular GLP-1 agonists may experience nail detachment, discoloration, and other issues at a significantly higher rate.
New research suggests that popular weight-loss injections, including Ozempic, Wegovy, and Mounjaro, are associated with a fourfold increase in the risk of nail detachment and other nail-related ailments.
The study, presented at the European Academy of Dermatology and Venereology Congress in Austria, found that 60% of patients using these medications reported conditions such as loose nails and discoloration. In comparison, nail detachment was significantly more common among users of these jabs.
Researchers believe that these injections, known as GLP-1 agonists, may trigger nutrient deficiencies, leading to a lack of keratin, a protein crucial for nail health. This deficiency, combined with the rapid weight loss induced by the drugs, can stress the body and redirect nutrients away from non-essential functions like nail growth.
Approximately 66% of jab users in the study reported at least one nail disorder, compared to just over half (53%) of patients who did not take the drugs. Nail discoloration affected 46% of drug users, versus 17% of non-users.
Even when compared to individuals who lost weight through diet and exercise, those using the injections were still more prone to nail problems. Severe calorie restriction associated with weight loss can also contribute to deficiencies in essential micronutrients like iron, zinc, and biotin, all vital for healthy nails.
Beyond nail issues, the study also highlighted scalp-related problems among users of these injections. Around half of individuals taking the drugs reported increased hair shedding, compared to just over a third of non-users. Hair thinning affected more than 40% of slimmers, and scalp redness was approximately three times more frequent in this group. These scalp symptoms were often accompanied by itching and scaling.
Dr. Charles Taïeb, the lead author, stated that the evidence of the drugs' effects on skin, hair, and nails is "not just anecdotal." Co-author Dr. Bruno Halioua added that doctors may commonly overlook the impact of these injections on scalp health, noting that while hair loss is a known side effect, the accompanying scalp inflammation might be underestimated. He emphasized that these conditions are generally treatable with moisturizers and steroid creams.
Hair thinning is already listed as a common side effect for these medications, which are used by millions. Data from the UK's Medicines and Healthcare products Regulatory Agency indicated hundreds of reports of hair loss linked to tirzepatide (Mounjaro) and hundreds more associated with Wegovy and Ozempic since the beginning of 2025. Previous analyses suggest this hair loss is a form of non-scarring alopecia, with the potential for regrowth.
While these side effects are concerning, Dr. Halioua advised that they are not typically a reason to discontinue treatment. However, he encouraged patients experiencing hair shedding, itchy red scalps, or nail changes to consult their doctor.